Zhejiang Wenda Pharmaceutical Technology has received Breakthrough Therapy Designation from China’s National Medical Products Administration for NHWD-870 HCI, its novel oral BET inhibitor being developed for advanced thoracic midline NUT carcinoma in patients who have failed prior chemotherapy.
The designation is significant because NUT carcinoma remains a rare and highly aggressive cancer with few effective treatment options. The disease is characterised by NUTM1 gene rearrangement and is often diagnosed at an advanced stage due to non-specific clinical symptoms and limited awareness.
According to the company, NUT carcinoma has a median survival of approximately 6.5 months and commonly occurs in the lungs, head and neck regions. The median age of onset is reported to be 23.6 years, underscoring the clinical impact of the disease on younger patients.
There is currently no globally approved targeted drug for NUT carcinoma. For clinicians and patients, this has meant reliance on existing treatment approaches that may offer limited durability, particularly in advanced disease after chemotherapy failure.
NHWD-870 HCI is being positioned as a targeted therapy candidate for this gap. As an oral small-molecule BET inhibitor, the drug is intended to address the biology of NUT carcinoma more directly than conventional symptomatic or chemotherapy-based approaches.
The Breakthrough Therapy Designation was granted based on Phase II clinical study data. As of December 27, 2025, 40 evaluable patients with advanced NUT carcinoma had been enrolled. Among 20 patients with advanced thoracic NUT carcinoma, the objective response rate reached 45.00 per cent.
The company also reported that median overall survival reached 9.33 months for both advanced thoracic NUT carcinoma patients and the full study population. Preliminary safety data indicated that NHWD-870 HCI was generally well tolerated, with some patients continuing treatment and follow-up.
From a regulatory perspective, the designation may help accelerate development and review in China. This could be especially relevant for rare cancers where limited patient numbers and urgent clinical need make conventional development pathways more difficult.
The broader importance of NHWD-870 lies in its potential to move NUT carcinoma treatment toward a more precision-targeted model. If future regulatory review supports approval, the drug could provide a new option for patients with advanced disease while strengthening China’s role in rare oncology drug innovation.
